RVL Pharmaceuticals PLC (RVLPQ)
RVL Pharmaceuticals plc is a specialty pharmaceutical company with operations in the United States, Argentina, and Hungary. The company develops and commercializes medicines aimed at underserved patient groups, with an emphasis on the ocular and medical aesthetics areas. Its commercial product includes Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution used to treat acquired blepharoptosis, or low-lying eyelid, in adults. RVL Pharmaceuticals was previously known as Osmotica Pharmaceuticals plc and adopted its current name in January 2022. The company is headquartered in Bridgewater, New Jersey. Its common stock is listed on OTC Markets under the symbol RVLP.Q.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-RVLP.Q
|
—
|
—
|
—
|
—
|
—
|
—
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 10, 2026
|
—
|
—
|
—
|
0.111 K
|
—
|
—
|
—
|
—
|
—
|
—
|
